Advertisements
Feeds:
Posts
Comments

What's The Big Data?

AI-Automation_potentialMGI:

Overall, we estimate that about half of the activities that people are paid almost $15 trillion to do in the global economy have the potential to be automated by adapting currently demonstrated technology…

All occupations will be affected. Only a small proportion of all occupations, about 5%, consist of 100% of activities that are fully automatable using currently demonstrated technologies. However, we find that about 30% of the activities in 60% of all occupations could be automated. This means that many workers will work alongside rapidly evolving machines, which will require worker skills also [to] evolve. This rapid evolution in the nature of work will affect everyone from welders to landscape gardeners, mortgage brokers—and CEOs; we estimate about 25% of CEOs’ time is currently spent on activities that machines could do, such as analyzing reports and data to inform decisions.

View original post

Advertisements

Cause of Alzheimer’s Discovered: protein SIRT6 role in DNA repair process – low levels enable DNA damage accumulation

Reporter: Aviva Lev-Ari, PhD, RN

 

According to lead author Dr. Deborah Toiber of the BGU Department of Life Sciences, “If a decrease in SIRT6 and lack of DNA repair is the beginning of the chain that ends in neurodegenerative diseases in seniors, then we should be focusing our research on how to maintain production of SIRT6 and avoid the DNA damage that leads to these diseases.”

Publications

Neuroprotective functions for the histone deacetylase SIRT6

Shai Kaluski Miguel Portillo, Antoine Besnard, Daniel Stein, Monica Einav, Lei Zhong, Uwe Ueberham, Thomas Arendt, Raul Mostoslavsky, Amar Sahay, Debra Toiber

Cell Reports 2017 Mar 28;18(13):3052-3062

Long noncoding RNA: noncoding and not coded.

Toiber D, Leprivier G, Rotblat B.

Cell Death Discov. 2017 Jan 9;3:16104. doi: 10.1038/cddiscovery.2016.104.

SIRT6 recruits SNF2H to DNA break sites, preventing genomic instability through chromatin remodeling.

Toiber D, Erdel F, Bouazoune K, Silberman DM, Zhong L, Mulligan P, Sebastian C, Cosentino C, Martinez-Pastor B, Giacosa S, D’Urso A, Näär AM, Kingston R, Rippe K, Mostoslavsky R.

Mol Cell. 2013 Aug 22;51(4):454-68. doi: 10.1016/j.molcel.2013.06.018.

The histone deacetylase SIRT6 is a tumor suppressor that controls cancer metabolism.

Sebastián C, Zwaans BM, Silberman DM, Gymrek M, Goren A, Zhong L, Ram O, Truelove J, Guimaraes AR, Toiber D, Cosentino C, Greenson JK, MacDonald AI, McGlynn L, Maxwell F, Edwards J, Giacosa S, Guccione E, Weissleder R, Bernstein BE, Regev A, Shiels PG, Lombard DB, Mostoslavsky R.

Cell. 2012 Dec 7;151(6):1185-99. doi: 10.1016/j.cell.2012.10.047.

Sirt1 is a regulator of bone mass and a repressor of Sost encoding for sclerostin, a bone formation inhibitor.

Cohen-Kfir E, Artsi H, Levin A, Abramowitz E, Bajayo A, Gurt I, Zhong L, D’Urso A, Toiber D, Mostoslavsky R, Dresner-Pollak R.

Endocrinology. 2011 Dec;152(12):4514-24. doi: 10.1210/en.2011-1128.

Characterization of nuclear sirtuins: molecular mechanisms and physiological relevance.

Toiber D, Sebastian C, Mostoslavsky R.

Handb Exp Pharmacol. 2011; 206:189-224. doi: 10.1007/978-3-642-21631-2_9.

A SIRT1-LSD1 corepressor complex regulates Notch target gene expression and development.

Mulligan P, Yang F, Di Stefano L, Ji JY, Ouyang J, Nishikawa JL, Toiber D, Kulkarni M, Wang Q, Najafi-Shoushtari SH, Mostoslavsky R, Gygi SP, Gill G, Dyson NJ, Näär AM.

Mol Cell. 2011 Jun 10;42(5):689-99. doi: 10.1016/j.molcel.2011.04.020.

Engineering DYRK1A overdosage yields Down syndrome-characteristic cortical splicing aberrations.

Toiber D, Azkona G, Ben-Ari S, Torán N, Soreq H, Dierssen M.

Neurobiol Dis. 2010 Oct;40(1):348-59. doi: 10.1016/j.nbd.2010.06.011.

Acetylcholinesterase variants in Alzheimer’s disease: from neuroprotection to programmed cell death.

Greenberg DS, Toiber D, Berson A, Soreq H.

Neurodegener Dis. 2010;7(1-3):60-3. doi: 10.1159/000285507.

The histone deacetylase Sirt6 regulates glucose homeostasis via Hif1alpha.

Zhong L, D’Urso A, Toiber D, Sebastian C, Henry RE, Vadysirisack DD, Guimaraes A, Marinelli B, Wikstrom JD, Nir T, Clish CB, Vaitheesvaran B, Iliopoulos O, Kurland I, Dor Y, Weissleder R, Shirihai OS, Ellisen LW, Espinosa JM, Mostoslavsky R.

Cell. 2010 Jan 22;140(2):280-93. doi: 10.1016/j.cell.2009.12.041.

Pro-apoptotic protein-protein interactions of the extended N-AChE terminus.

Toiber D, Greenberg DS, Soreq H.

J Neural Transm 2009 Nov;116(11):1435-42. doi: 10.1007/s00702-009-0249-2.

N-acetylcholinesterase-induced apoptosis in Alzheimer’s disease.

Toiber D, Berson A, Greenberg D, Melamed-Book N, Diamant S, Soreq H.

PLoS One. 2008 Sep 1;3(9):e3108. doi: 10.1371/journal.pone.0003108.

A novel isoform of acetylcholinesterase exacerbates photoreceptors death after photic stress.

Kehat R, Zemel E, Cuenca N, Evron T, Toiber D, Loewenstein A, Soreq H, Perlman I.

Invest Ophthalmol Vis Sci. 2007 Mar;48(3):1290-7.

Modulated splicing-associated gene expression in P19 cells expressing distinct acetylcholinesterase splice variants.

Ben-Ari S*, Toiber D*, Sas AS, Soreq H, Ben-Shaul Y.

J Neurochem. 2006 Apr;97 Suppl 1:24-34.

  • ​*Equal contribution

Cellular stress reactions as putative cholinergic links in Alzheimer’s disease.

Toiber D, Soreq H.

Neurochem Res. 2005 Jun-Jul;30(6-7):909-19.

Function of alternative splicing.

Stamm S, Ben-Ari S, Rafalska I, Tang Y, Zhang Z, Toiber D, Thanaraj TA, Soreq H.

Gene. 2005 Jan 3;344:1-20.

Combinatorial complexity of 5′ alternative acetylcholinesterase transcripts and protein products.

Meshorer E, Toiber D, Zurel D, Sahly I, Dori A, Cagnano E, Schreiber L, Grisaru D, Tronche F, Soreq H.

J Biol Chem. 2004 Jul 9;279(28):29740-51.

SOURCE

https://toiber.wixsite.com/toiber-lab/publications


Ultra-Pure Melatonin Product Helps Maintain Sleep for Up to 7 Hours

Curator: Gail S. Thornton, M.A.

Co-Editor: The VOICES of Patients, Hospital CEOs, HealthCare Providers, Caregivers and Families: Personal Experience with Critical Care and Invasive Medical Procedures

 

The role of melatonin is important in regulating natural sleep and wake cycles. Typically, melatonin levels decline with age, significantly decreasing after age 40. An estimated 50 to 70 million Americans are affected by sleep difficulties – a process regulated by melatonin — and long-term sleep deprivation has been associated with negative health consequences, including an increased risk of diabetes, hypertension, heart attack, stroke, obesity, and depression.

Clinical data from a new pharmacokinetic study suggests that REMfresh®, the first and only continuous release and absorption melatonin (CRA-melatonin), helps maintain sleep for up to 7 hours. REMfresh® contains 99 percent ultra-pure melatonin and is sourced in Western Europe, a factor that is significant and important to many sleep specialists.

Three research abstracts on the REMfresh® data were published in an online supplement in the journal, Sleep, and were presented recently at the 31st Annual Meeting of the Associated Professional Sleep Societies LLC (APSS).

REMfresh Photo

Image SOURCE: Photograph courtesy of Physician’s Seal®

How REMfresh® Works

REMfresh® (CRA-melatonin) mimics the body’s own 7-hour Mesa Wave™, a natural pattern of melatonin blood levels during a normal night’s sleep cycle.

The study demonstrated the continuous release and absorption of 99 percent ultra-pure melatonin in REMfresh® (CRA-melatonin) was designed to induce sleep onset and provide continuous, lasting restorative sleep over 7 hours.

The scientifically advanced, patented formulation, called Ion Powered Pump (IPP™) technology, replicates the way in which the body naturally releases and absorbs melatonin, unlike conventional melatonin sleep products.

Since REMfresh® (CRA-melatonin) is not a drug, there is no drug hangover.

REMfresh MesaCurveNew-1

Image SOURCE: Diagram courtesy of Physician’s Seal®

 

Data Based on Scientifically Advanced Delivery Technology

According to the primary study author, David C. Brodner, M.D., “These study results represent an unparalleled breakthrough in drug-free, sleep maintenance that physicians and patients have been waiting for in a sleep product.” Dr. Brodner is a sleep specialist who is double board-certified in Otolaryngology – Head and Neck Surgery and Sleep Medicine and is the founder and principle physician at the Center for Sinus, Allergy, and Sleep Wellness in Palm Beach County, Florida.

Dr. Brodner said, “Melatonin products have been used primarily as a chronobiotic to address sleep disorders, such as jet lag and shift work. The patented delivery system in REMfresh mimics the body’s own natural sleep pattern, so individuals may experience consistent, restorative sleep and have an improved quality of life with this drug-free product.”

Study Findings With REMAKT

The study findings are based on REMAKT™ (REM Absorption Kinetics Trial), a U.S.-based randomized, crossover pharmacokinetic (PK) evaluation study in healthy, non-smoking adults that compared REMfresh® (CRA-melatonin) with a market-leading, immediate-release melatonin (IR-melatonin).

The study found that melatonin levels with REMfresh® exceeded the targeted sleep maintenance threshold for a median of 6.7 hours, compared with 3.7 hours with the leading IR-melatonin. Conversely, the levels of the market-leading IR-melatonin formulation dramatically increased 23 times greater than the targeted levels of exogenous melatonin for sleep maintenance and had a rapid decline in serum levels that did not allow melatonin levels to be maintained beyond 4 hours.

Additional analysis presented showed that REMfresh® (CRA-melatonin) builds upon the body of evidence from prolonged-release melatonin (PR-M), which demonstrated in well-conducted, placebo-controlled studies, statistically significant improvement in sleep quality, morning alertness, sleep latency and quality of life in patients aged 55 years and older compared with placebo.

REMfresh® (CRA-melatonin) was designed to overcome the challenges of absorption in the intestines, thereby extending the continual and gradual release pattern of melatonin through the night (known as the Mesa Wave™, a flat-topped hill with steep sides). There was a faster time to Cmax, which is anticipated to result in improved sleep onset, while the extended median plateau time to 6.7 hours and rapid fall-off in plasma levels at the end of the Mesa Wave™ may help to improve sleep maintenance and morning alertness.

REFERENCE/SOURCE

Physician’s Seal® and REMfresh® (www.remfresh.com)

REMfresh® press release, June 5, 2017 (http://www.prnewswire.com/news-releases/scientifically-advanced-delivery-technology-in-sleep-management-debuts-at-sleep-2017-with-clinical-data-showing-remfresh-the-first-and-only-continuous-release-and-absorption-melatonin-helps-maintain-sleep-for-up-to-7-hours-300468218.html)

Dr. David C. Brodner, Center for Sinus, Allergy, and Sleep Wellness  (http://www.brodnermd.com/sleep-hygiene.html)

Other related articles published in this Open Access Online Scientific Journal include the following:

2017

Sleep Research Society announces 2017 award recipients including Thomas S. Kilduff, PhD, Director, Center for Neuroscience at SRI International in Menlo Park, California

https://pharmaceuticalintelligence.com/2017/04/28/sleep-research-society-announces-2017-award-recipients-including-thomas-s-kilduff-phd-director-center-for-neuroscience-at-sri-international-in-menlo-park-california/

2016

Sleep Science

Genetic link to sleep and mood disorders

https://pharmaceuticalintelligence.com/2016/02/27/genetic-link-to-sleep-and-mood-disorders/

2015

Sleep quality, amyloid and cognitive decline

https://pharmaceuticalintelligence.com/2015/10/31/sleep-quality-amyloid-and-cognitive-decline/

2013

Day and Night Variation in Melatonin Level affects Plasma Membrane Redox System in Red Blood Cells

https://pharmaceuticalintelligence.com/2013/02/23/httpwww-ncbi-nlm-nih-govpubmed22561555/


The Future of Hospitals – How Medical Care and Technology Work Together to Advance Patient Care 

Curator: Gail S. Thornton, M.A.

Co-Editor: The VOICES of Patients, Hospital CEOs, HealthCare Providers, Caregivers and Families: Personal Experience with Critical Care and Invasive Medical Procedures

 

Gap Medics (https://www.gapmedics.com/blog/), the world’s leading provider of hospital work experience placements for high school and university students, recently released their “Futuristic Hospitals” infographic. The infographic reviews a collection of top hospitals in the world based on several key factors:

  • overall patient care,
  • innovative medical and technological excellence,
  • efforts toward sustainability,
  • environmental stewardship, and
  • social responsibility, as well as
  • other innovative health care features

to help advance the field of medicine and, ultimately, patient care.

Futuristic Hospitals Infographic

Image SOURCE: Infographic of Futuristic Hospitals courtesy of Evolved Digital and Gap Medics. Reprinted here with Permission from the Source.

 

“Many leading hospital facilities are now rolling out significant improvements and changes that couldn’t have been envisioned 10 years ago,” said Ian McIntosh, Director, Evolved Digital (http://evolveddigital.co.uk/), a U.K.-based digital marketing company specializing in search engine optimization and content marketing, whose team created the infographic for Gap Medics.

Science and innovation are working together to help convey higher expectations for quality medical and health care and advancements in the hospital experience for health care providers, patients and their families.

Particularly, the infographic analyzed prominent hospitals around the world so patients and their families can learn about the latest advances and efforts in patient care and hospital and medical technology.

In this infographic, we investigated the most cutting-edge hospital facilities in the world, where best-in-class technology and innovative medical care are making a difference in providing a quality experience all over the world.

“Gap Medics creates programs offered to thousands of students from Europe, Asia and the United States so they have the opportunity to gain insights into the work of doctors, nurses, physician assistants, midwives and dentists before the students begin their clinical training,” said Dave Brown, Director, Gap Medics, a U.K.-based company that provides hospital work experience between 1-8 weeks to students 16 years of age and older.

This one-in-a-lifetime opportunity helps students better understand their chosen career path, develop as people, and strengthen their university application process.

 

REFERENCE/SOURCE

http://evolveddigital.co.uk/

https://www.gapmedics.com/blog/2017/03/27/futuristic-hospitals/

Other related articles published in this Open Access Online Scientific Journal include the following:

 

“Sudden Cardiac Death,” SudD is in Ferrer inCode’s Suite of Cardiovascular Genetic Tests to be Commercialized in the US

Curator: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2014/02/10/sudden-cardiac-death-sudd-is-in-ferrer-incodes-suite-of-cardiovascular-genetic-tests-to-be-commercialized-in-the-us/

 

Hybrid Cath Lab/OR Suite’s da Vinci Surgical Robot of Intuitive Surgical gets FDA Warning Letter on Robot Track Record

Reporter: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2013/07/19/hybrid-cath-labor-suites-da-vinci-surgical-robot-of-intuitive-surgical-gets-fda-warning-letter-on-robot-track-record/

 

3D Cardiovascular Theater – Hybrid Cath Lab/OR Suite, Hybrid Surgery, Complications Post PCI and Repeat Sternotomy

Curator: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2013/07/19/3d-cardiovascular-theater-hybrid-cath-labor-suite-hybrid-surgery-complications-post-pci-and-repeat-sternotomy/



Tweets HIGHLIGHTS from 11th US-India BioPharma & Healthcare Summit, Thursday, May 18, 2017, Boston Marriott Cambridge

 @pharma_BI @AVIVA1950 @USAIC 

USAIC Retweeted your Tweet

11h11 hours ago

Aviva Lev-Ari @AVIVA1950

@pharma_BI @AVIVA1950 @USAIC #USAIC17 Amrit Ray, CMO, Janssen In India, what is the philosophy on alignment FDA, other regulatory

9 other Retweets

Adam Pulwer Retweeted your reply

11h11 hours ago

Aviva Lev-Ari @AVIVA1950

@pharma_BI @AVIVA1950 @USAIC #USAIC17 Dr. James Bradner, Novartis, active in CRISPR, technology from outside invited in

iboss liked your reply

 

May 18

Aviva Lev-Ari @AVIVA1950

@pharma_BI @AVIVA1950 @USAIC #USAIC17 Dr. William Chin, Executive Vice President and CMO, PhRMA Patient’s Compliance, control investigation

 

Publicity.ai liked your reply

May 18

Aviva Lev-Ari @AVIVA1950

@pharma_BI @AVIVA1950 @USAIC #USAIC17 Dr. William Chin, Executive Vice President and CMO, PhRMA HOW to reduce Failure in Trials??

Dan Nedelko liked your reply

May 18

Aviva Lev-Ari @AVIVA1950

@pharma_BI @AVIVA1950 @USAIC #USAIC17 Dr. Michael Rosenblatt, CMO, Flagship Pioneering, Right to TRY, does that exist in India?

  1. Genomics Press liked your replies

May 18

Aviva Lev-Ari @AVIVA1950

@pharma_BI @AVIVA1950 @USAIC #USAIC17 Dr. Richard Moscicki, USFDA Frequensist Analysis at FDA, Precision medicine requires Bayesian approach

1 other like

Zeal Caiden liked your reply

 

May 18

Aviva Lev-Ari @AVIVA1950

@pharma_BI @AVIVA1950 @USAIC #USAIC17 Amrit Ray, CMO, Janssen In India, what is the philosophy on alignment FDA, other regulatory

  1. USAICRetweeted your Tweet

 

May 18

Aviva Lev-Ari @AVIVA1950

@pharma_BI @AVIVA1950 @USAIC #USAIC17 Panel on Vaccines – How do we make Vaccines more affordable for Populations, oral and stable

1 other Retweet

 

Retweeted

several companies are chasing ONE molecule, the same one

Retweeted

Vaccines Dr. Stephen Caddick, Wellcome Trust, use vaccine to mitigate bacterial resistance

Retweeted

Panel on Vaccines – How do we make Vaccines more affordable for Populations, oral and stable

Retweeted

We start NOW LIVE REAL TIME – 11th US-India BioPharma & Healthcare Summit, 5/18 Marriott Cambridge

Vaccines Dr. Stephen Caddick, Wellcome Trust, use vaccine to mitigate bacterial resistance

Panel on Vaccines – How do we make Vaccines more affordable for Populations, oral and stable

LIVE – 11th US-India BioPharma & Healthcare Summit, Thursday, May 18, 2017, Boston Marriott Cambridge, 50 Broadway,…


LIVE 11th US-India BioPharma & Healthcare Summit, Thursday, May 18, 2017, Boston Marriott Cambridge, 50 Broadway, Cambridge

Aviva Lev-Ari, PhD, RN at LPBI Group will cover the event in Real Time

@pharma_BI

@AVIVA1950

@USAIC

11th US-India BioPharma & Healthcare Summit, Thursday, May 18, 2017, Boston Marriott Cambridge, 50 Broadway, Cambridge

BioPharma & Healthcare Summit 2017

Emcee – Dr. Andrew Plump, Chief Medical & Scientific Officer, Takeda

* Speakers and Timings subject to change

Time Topic
8-45 AM – 9-15 AM Registration and Networking
9-15 AM – 9-30 AM Welcome address by Karun Rishi, President, USA-India Chamber of Commerce

Opening comments by – Dr Andrew Plump, Chief Medical & Scientific Officer, Member of the Board of Directors, Takeda Pharmaceuticals

  1. Value and Access in Healthcare vs Innovations, Patients,
  2. Value in HealthCare is relative to time and location
  3. massive underserved population
  4. Access: whoever Patients are and whereever they are
  5. In India 1.3 Billion people, 70% of World population and HealthCare spending is 1% of World cost of HealthCare – need for investment ans development of infrastructure
9-30 AM – 9-55 AM India Regulatory and Clinical Research Update*
Dr. R.K. Vats , IAS, Additional Secretary, Ministry of Health and Family Welfare, Government of India
9-55 AM – 10-45 AM Panel Discussion: Oncology

  1. Immunotherapy – Tumor cells, necrosis, mutation, Response to T-Cell therapy and Tumor shrinkage
  2. What is the mechanism to enable Oncology drugs in China and India
  3. Oncology Drug are two expensive
  4. Melanoma gets best response to PD-1
  5. We might not have found the right Checkpoint molecule, new agonist therapies, new antigens
  6. Oncolytic Viruses – for tumors that do not respond to immuno therapy
  7. Combination therapy, increase in Toxicity
  8. Toxicity – Cerebral edema during clinical trials of immunotherapy
  9. Upregulation and Downregulation dependent on dosing in immuno-therapy

Panelists:

  • Dr. Edward Benz, President & CEO Emeritus, Dana Farber Cancer Institute
    1. Durable response, immuno-suppression, biological role in tumor surveillence, Checkpoint opens up the use of vaccines
    2. Block of 50 molecules
    3. How can we learn more on the Translational and Clinical level – getting smarter – HOW
    4. Screening Patients: Immuno-phynotyping, predicting markers,
  • Dr. Rakesh Jain, E.L. Steele Laboratory of Tumor Biology,  MGH Cancer Center/ Harvard Medical School
  • Dr. Timothy Clackson, President R&D and CSO, Ariad Pharmaceuticals
  • Dr. Chandru, Chairman, Strand Life Sciences
  1. Licensing HepC will be very important
  • Dr. Jeffrey Engelman, Global Head of Oncology Research, Novartis Institutes for BioMedical Research
  1. PD-1 is $50,000 a year therapy, In India affordable pricing
  2. Collaboration: PACK –  few companies and Academic – focus on immunotherapy,
  3. Foundation Medicine biomarkers Platform
  4. What is the mutation burden which will predict the response to PD-1

 

Moderator:
Dr. Vijay Kuchroo, Director- Evergrande Center for Immunologic Diseases, Brigham & Women’s Hospital/ Harvard Medical School

10-45 AM – 11-15 AM *Fireside Chat on Govnt’t Agency, Advocacy Groups, Big Phara, NIH, FDA

  • Dr. Richard Moscicki, ex-Genzyme, Deputy Director (Science Operations), Center for Drug Evaluation and Research, USFDA and
  1. Since 2004, 40 Public-Private Partnerships, relationships with NIH
  2. External relationships, where are the Scientists going,
  3. Toxicology, Biomarkers, Lexicon,
  • Dr. Chris Austin, Director, National Center for Advancing Translational Sciences, NIH
  1. Academic and Biotech companies relations: Toxicity testing, new clinical trial design, increase efficiency
  2. Knowledge of disease increased vastly
  3. HealthCare not at the same rate
  4. Rare disease tested on 5,000 patients, Genomics combinatories
  5. Clinical Trial Templets: FDA & NIH working together on
  6. FDA & DARPA – Tissue engineering
  7. mainatin Statistical Robustness yet change the process
  • Dr. R.K. Vats , IAS, Additional Secretary, Ministry of Health and Family Welfare, Government of India

 

  • Moderator:
    Dr. William Chin, Executive Vice President and Chief Medical Officer, PhRMA
  1. Efficiency of Clinical Trial needs improvement
  2. Gene therapy in US: Interaction between NIH and FDA – how is it going
11-15 AM -11-45 AM Networking & Tea Break
11-45 AM – 12-35 PM Panel Discussion: Vaccines

Panelists:

  • Dr. Stephen Caddick, Director of Innovation, Wellcome Trust
  1. management health in decline
  2. scientific complexity
  3. Science, Technology and Understanding Human Behavior neede NOT to fail society
  • Dr. Johan Van Hoof, Global Therapeutic Head- Infectious Diseases & Vaccines, Janssen Pharmaceutical Companies of Johnson & Johnson
  • Dr. Gagandeep Kang, Executive Director, Translational Health Science & Technology Institute (THISTI)
  1. Clinical Trial Design in India, integrated IRB system for evaluation
  • Michael Nally, President, Merck Vaccines, Merck & Co.
  • Dr. Niranjan Sardesai, Chief Operating Officer, Inovio Pharmaceuticals

Moderator:
Dr. William Chin, Executive Vice President and Chief Medical Officer, PhRMA

  1. Necessary expertise on emerging infectious agents
  2. Affordability of Vaccine
  3. More discussion needed on Vaccines
12-35 PM – 1-05 PM Fireside Chat with

  • Sanat Chattopadhyay, President, Merck Manufacturing Division, Merck & Co.;
  • Dr. R. K. Vats, IAS, Additional Secretary, Ministry of Health and Family Welfare, Government of India; Alok Kumar, Advisor, Niti Aayog*

Moderator:
Dr. Amrit Ray, Chief Medical Officer, Janssen Pharmaceutical Companies of Johnson & Johnson

1-05 PM – 2-40 PM Luncheon Panel Discussion: Clinical Trials & Regulatory

Panelists:

    • Dr. Richard Moscicki, Deputy Director (Science Operations), CDER, USFDA
    • Dr. Petra Kaufmann, Director, Office of Rare Diseases Research & Director, Division of Clinical Innovations – NCATS, NIH
    • Dr. G.N. Singh, Drug Controller General of India, Central Drugs Standard Control Organization, Ministry of Health
    • K.V. Subramaniam, President, Reliance Life Sciences
  • Dr. William Chin, Executive Vice President and Chief Medical Officer, PhRMA
  1. Patient’s Compliance, control investigation
  2. Value to Patient, what value do they ask for

Moderator:
Dr. Michael Rosenblatt, Chief Medical Officer, Flagship Pioneering

2-40 PM – 3-15 PM Networking & Tea Break
3-15 PM – 4-05 PM Panel Discussion: Rare & Neglected Diseases

Panelists:

  • Dr. Chris Austin, Director, National Center for Advancing Translational Sciences, National Institutes of Health
  • Dr. Jim Burns, President and CEO, Casebia Therapeutics
  • Dr David Meeker, Executive Vice President & Head, Sanofi Genzyme
  • Dr. Wim Parys, Head of R&D- Global Public Health, Janssen Pharmaceutical companies of Johnson & Johnson
  • Dr. Alfred Sandrock, Executive Vice President & Chief Medical Officer, Biogen

Moderator:
Dr. Steve Uden, Head of Research, Alexion Pharmaceuticals

4-05 PM – 4-55 PM Panel Discussion: Drug Discovery and Development

Panelists:

  • Dr. James Bradner, President, Novartis Institutes for BioMedical Research
  • Dr. William Hait, Global Head- Research & Development, Janssen Pharmaceutical Companies of Johnson & Johnson
  • Dr Andrew Plump, Chief Medical & Scientific Officer and Director, Takeda Pharmaceuticals
  1. Clinical Partnerships important, last molecule developed in house in 1999, Partnershiip in Stem Cells, development for Ciliac disease
  • Dr. David Nicholson, Chief R&D Officer, Allergan
  1. R&D is small Intell Group to identify opportunities is large, 2,500

Moderator:
Dr. Martin Mackay, Executive Vice President and Global Head of R&D, Alexion Pharmaceuticals

4-55 PM – 5-00 PM Closing Remarks
5-00 PM – 6-30 PM Cocktails & Networking Reception